New cancer drug HLX42 enters first human trial

NCT ID NCT06210815

Recruiting now Disease control Sponsor: Shanghai Henlius Biotech Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial tests HLX42, a drug that targets a protein called EGFR found on some cancer cells. The drug delivers a powerful chemotherapy directly to the tumor. The study involves about 100 adults with advanced solid tumors, including non-small cell lung cancer, who have run out of standard options. The main goal is to check safety and find the best dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HLX42 (an antibody-drug conjugate that targets EGFR and delivers a chemotherapy drug directly to cancer cells)
What this could lead to: If successful, this could lead to a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong: This is an early Phase 1 trial with only 102 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR AND NSCLC

Contacts and locations

Locations

Guangdong Provincial People's Hospital
RECRUITING

Guangdong, Guangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.